Medical Technology

@techcrunch.com 2 years ago

How Colossal sold investors on a quest to resurrect a woolly mammoth

@Primary_Immune 3 years ago

🧬 A nice update on gene therapy '2.0' ...like the ring of "genes as medicines" :-) https://www.nature.com/articles/s41467-020-19507-0 #openscience #datascience #bigdata #rstats #technology #biotech #itrtg #genomics #raredisease https://t.co/EMUZn1AXBO

@xconomy.com 3 years ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 3 years ago

FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products

@xconomy.com 4 years ago

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

@xconomy.com 4 years ago

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

@xconomy.com 4 years ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 4 years ago

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

@xconomy.com 4 years ago

Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits

@xconomy.com 5 years ago

Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More

@xconomy.com 5 years ago

In Landmark Gene-Editing Study, Sangamo Reports Little Benefit

@xconomy.com 5 years ago

Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More

@xconomy.com 5 years ago

Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial

@xconomy.com 5 years ago

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M

@techcrunch.com 6 years ago

With $250 million, Peter Diamandis’ new startup is all about taking stem cells from placentas